Get the Ricochet app

Ricochet will work fine in a browser on your mobile devices, but for the best experience please download our app.

Download on the App StoreGet it on Google Play

Become a member.

Tired of the toxicity of social media? Why not join Ricochet for just $5/month? Think of it as an online bar. Come in, have a drink, hang out, say whatever you want. But don’t badger, bully, or berate the other drinkers. That's our only rule.

Breast Cancer Risk: Testing to Tailored Screening, Treatment, and Prevention

Subscribe to HubwonkSubscribe

Joe Selvaggi talks with precision medicine expert, Alva 10 CEO Hannah Mamuszka about how individualized testing can both detect and substantially reduce the incidence of breast cancer, a disease that accounts for more than 40,000 deaths each year.

Guests:

Hannah Mamuszka is Founder & CEO of ALVA10, a healthcare technology firm. Hannah has spent her 20+ year career in diagnostics – both in pharma and at diagnostics companies, in the lab and on the business side. She believes that the challenges of diagnostic technology fully impacting patient care are more commercial than technical, and conceived of ALVA10 to create a mechanism to pull technology into healthcare by aligning incentives through data. She regularly speaks on issues regarding advancement of technology in healthcare, is on the Board of Directors for two diagnostic companies and writes a column on the value of diagnostics for the Journal of Precision Medicine.

Host:
Joe Selvaggi
Guest:
HMHannah Mamuszka